- 24/7 Technology,Internet,Bio Patent and Intellectual Property News & Information Service
-
SUBSCRIBE TO FEED
- Who are patent attorneys?
- What are patents, and how long are they in force?
- Valuing patents
- Steps in the Patent Process
- Intellectual Property and patents thereof
- History of Patents and Patent Law
- Copyrights & Copyright Law History
- Historically Famous U.S. patents
- Comparing Patents & Copyrights
- Applying for a Patent? Follow these steps
-
Articles
'Data' Tag
-
Affymetrix releases new data for rapid design of custom arrays
July 27, 2010[Story ID: 3278] Affymetrix, Inc.today announced that it has released an unparalleled data set based on extensive validation of novel SNPs from the 1000 Genomes Project. This data will give researchers access to more rare mutations for genome-wide association studies and will enable the rapid design of custom arrays for a variety of applications, including [...]
-
Mice treated with XOMA 052 experiences improvement in measures associated with diabetes: Endocrinology
June 23, 2010[Story ID: 2456] XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced the publication of data from a mouse model of diet-induced obesity in the June, 2010 edition of the journal Endocrinology. The data showed that mice treated with XOMA 052 both prophylactically and therapeutically experienced improvement in measures associated with [...]
-
Data from Phase 1 study of FOLOTYN in patients with relapsed or refractory CTCL presented at EHA 2010
June 11, 2010[Story ID: 2288] Allos Therapeutics, Inc. today announced updated data from its ongoing dose finding Phase 1 study of FOLOTYN (pralatrexate injection) in patients with relapsed or refractory cutaneous T-cell lymphoma, a group of often slow-growing non-Hodgkins lymphomas that primarily manifest in the skin. These data were presented during a poster presentation at the European [...]
-
Erlotinib shows great benefit in women with lung cancer: Study
June 8, 2010[Story ID: 2210] Three times as many women with advanced lung cancer were alive and had no progression of their cancer 12 months after taking the drug erlotinib (also known as Tarceva) compared to those who did not receive the drug according to new data being presented at the ASCO1 conference today (Monday).
-
Cyclacel reports positive interim data from sapacitabine Phase 2 study for myelodysplastic syndromes
June 8, 2010[Story ID: 2214] Cyclacel Pharmaceuticals, Inc. announced today interim response data from a Phase 2 randomized trial of oral sapacitabine capsules, a novel nucleoside analogue, in older patients with myelodysplastic syndromes (MDS) that have failed hypomethylating agents. The data were presented at an oral poster discussion session at the 2010 American Society of Clinical Oncology [...]
-
AIR Trial demonstrates benefits of BT in asthma patients
May 20, 2010[Story ID: 1919] Asthmatx Inc., today presented positive five-year data from the Asthma Intervention Research Trial, which evaluated the safety of bronchial thermoplasty with the Alair System. The data demonstrated the absence of clinical complications and the maintenance of stable lung function over a five year period post-BT in patients with moderate to severe asthma.
-
No increase in risk of glioma or meningioma with use of mobile phones: INTERPHONE project
May 17, 2010[Story ID: 1870] The International Journal of Epidemiology today published a combined data analysis from a multi national population-based case-control study of glioma and meningioma, the most common types of brain tumour. This is the first in a series of combined data analyses of head and neck tumours published as part of the internationally coordinated [...]
-
TYZX Expands Portfolio With Two New Patents on High Performance Stereo Vision Systems
April 5, 2010[Story ID: 1144] MENLO PARK, CA–(Marketwire – April 5, 2010) – TYZX
-
Acologix presents preclinical study results of AC-100 on cartilage regeneration at ORS annual meeting
March 8, 2010[Story ID: 737] Acologix, Inc., a privately held biopharmaceutical company, today announced the results of its latest preclinical study demonstrating that AC-100, its therapeutic product candidate derived from an endogenous human protein, promotes cartilage regeneration in a large animal model. The data will be presented by Dr. David M. Rosen on March 6, 2010 at [...]
-
Poniard Pharmaceuticals picoplatin Phase 2 study in metastatic CRPC: Positive results
March 6, 2010[Story ID: 711] Poniard Pharmaceuticals, Inc., a biopharmaceutical company focused on innovative oncology therapies, today announced the presentation of positive final data, including survival data, from the Company’s Phase 2 clinical trial of picoplatin as a first-line therapy in men with metastatic castration-resistant (hormone-refractory) prostate cancer (CRPC). The results were presented in a General Poster [...]